Related references
Note: Only part of the references are listed.Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient
Jin-Jun Guo et al.
ANTIVIRAL RESEARCH (2009)
Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir
Maria Seifer et al.
ANTIVIRAL RESEARCH (2009)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2009)
Complex Dynamics of Hepatitis B Virus Resistance to Adefovir
Corahe Pallier et al.
HEPATOLOGY (2009)
Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen-Positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir
Nancy Leung et al.
HEPATOLOGY (2009)
The rtA194T Polymerase Mutation Impacts Viral Replication and Susceptibility to Tenofovir in Hepatitis B e Antigen-Positive and Hepatitis B e Antigen-Negative Hepatitis B Virus Strains
Samad Amini-Bavil-Olyaee et al.
HEPATOLOGY (2009)
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Maurizia Rossana Brunetto et al.
HEPATOLOGY (2009)
Side Effects of Long-Term Oral Antiviral Therapy for Hepatitis B
Robert J. Fontana
HEPATOLOGY (2009)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance
Nao Kurashige et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?
Yoshiyuki Suzuki et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy
Hyeok Choon Kwon et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
922 RESCUE THERAPY WITH COMBINATION OF ENTECAVIR AND TENOFOVIR IN PATIENTS WITH CHRONIC HBV, ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES IS SAFE AND HIGHLY EFFICIENT
M. Lütgehetmann et al.
JOURNAL OF HEPATOLOGY (2009)
HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B
M. Vigano et al.
JOURNAL OF HEPATOLOGY (2009)
EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS
F. van Boemmel et al.
JOURNAL OF HEPATOLOGY (2009)
EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION
F. van Boemmel et al.
JOURNAL OF HEPATOLOGY (2009)
OUTCOME OF HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHB) 5 YEARS AFTER DISCONTINUATION OF LONG TERM ADEFOVIR DIPIVOXIL (ADV) TREATMENT
S. Hadziyannis et al.
JOURNAL OF HEPATOLOGY (2009)
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy
Jurrien G. P. Reijnders et al.
JOURNAL OF HEPATOLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance
Bulent Degertekin et al.
JOURNAL OF HEPATOLOGY (2009)
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study
Rami Moucari et al.
JOURNAL OF HEPATOLOGY (2009)
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir
L. K. K. Tan et al.
JOURNAL OF VIRAL HEPATITIS (2009)
The Amount of Hepatocyte Turnover That Occurred during Resolution of Transient Hepadnavirus Infections Was Lower When Virus Replication Was Inhibited with Entecavir
William S. Mason et al.
JOURNAL OF VIROLOGY (2009)
Understanding the molecular basis of HBV drug resistance by molecular modeling
Ashoke Sharon et al.
ANTIVIRAL RESEARCH (2008)
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication
Brent E. Korba et al.
ANTIVIRAL RESEARCH (2008)
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update
Emmet B. Keeffe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study
Adriano M. Pellicelli et al.
CLINICAL THERAPEUTICS (2008)
Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C
Jean-Francois Rossignol et al.
FUTURE MICROBIOLOGY (2008)
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
Patrick Marcellin et al.
HEPATOLOGY (2008)
Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
Carl J. Baldick et al.
HEPATOLOGY (2008)
Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks
Morris Sherman et al.
HEPATOLOGY (2008)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2008)
73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE
F. van B¨ommel et al.
JOURNAL OF HEPATOLOGY (2008)
Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV)
T. Berg et al.
JOURNAL OF HEPATOLOGY (2008)
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up
Hiromi Yatsuji et al.
JOURNAL OF HEPATOLOGY (2008)
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic heptitis B
Chee-Kin Hui et al.
JOURNAL OF HEPATOLOGY (2008)
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
Joseph J. Y. Sung et al.
JOURNAL OF HEPATOLOGY (2008)
Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine
Silvia Gala et al.
JOURNAL OF HEPATOLOGY (2008)
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure
Stephanie Villet et al.
JOURNAL OF HEPATOLOGY (2008)
Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy
Samreen Ijaz et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical features of adverse reactions associated with telbivudine
Xue-Song Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Telbivudine versus lamivudine in patients with chronic hepatitis B
Ching-Lung Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response
Man-Fung Yuen et al.
HEPATOLOGY (2007)
Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay
Evelien Libbrecht et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients
Pie-Fro Lampertico et al.
GASTROENTEROLOGY (2007)
Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B
Robert G. Gish et al.
GASTROENTEROLOGY (2007)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Inhibition of hepatitis B virus polymerase by entecavir
David R. Langley et al.
JOURNAL OF VIROLOGY (2007)
In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication
Richard A. Heipertz et al.
JOURNAL OF VIROLOGY (2007)
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient
Stephanie Villet et al.
JOURNAL OF HEPATOLOGY (2007)
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
Irene Rapti et al.
HEPATOLOGY (2007)
Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B
Shiv Kumar Sarin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Tenofovir-induced kidney injury
Michael D. Gitman et al.
EXPERT OPINION ON DRUG SAFETY (2007)
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen
Stephanie A. Santos et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2006)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2006)
Entecavir resistance is rare in nucleoside naive patients with hepatitis B
Richard J. Colonno et al.
HEPATOLOGY (2006)
Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif
Hiromi Yatsuji et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
J. E. Yeon et al.
GUT (2006)
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn et al.
HEPATOLOGY (2006)
Evolution of multi-drug resistant hepatitis B virus during sequential therapy
Hyung Joon Yim et al.
HEPATOLOGY (2006)
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
Florian van Boemmel et al.
HEPATOLOGY (2006)
Antiviral drug resistance: Clinical consequences and molecular aspects
A Bartholorneusz et al.
SEMINARS IN LIVER DISEASE (2006)
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine
F Zoulim et al.
JOURNAL OF VIRAL HEPATITIS (2006)
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
TT Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
UH Iloeje et al.
GASTROENTEROLOGY (2006)
Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B:: HBsAg loss is associated with HBV genotype
HJ Flink et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
P Lampertico et al.
HEPATOLOGY (2005)
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
SK Fung et al.
JOURNAL OF HEPATOLOGY (2005)
Flares in chronic hepatitis B patients induced by the host or the virus?: Relation to treatment response during Peg-interferon α-2b therapy
HJ Flink et al.
GUT (2005)
Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants
AA van der Eijk et al.
JOURNAL OF VIRAL HEPATITIS (2005)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
SJ Hadziyannis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
M van Zonneveld et al.
HEPATOLOGY (2004)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine
DJ Tenney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B
S Gaia et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
F van Bömmel et al.
HEPATOLOGY (2004)
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
MG Peters et al.
GASTROENTEROLOGY (2004)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
P Angus et al.
GASTROENTEROLOGY (2003)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
ASF Lok et al.
GASTROENTEROLOGY (2003)
Antiviral activity of interferon-α against hepatitis B virus can be studied in non-hepatic cells and is independent of MxA
A Rang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alfa
MA Rico et al.
HEPATOLOGY (2001)
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
R Perrillo et al.
HEPATOLOGY (2000)
Share Paper
